Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics


Reata Pharmaceuticals, Inc. - (RETA): $145.97

-0.04 (-0.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RETA POWR Grades


  • Sentiment is the dimension where RETA ranks best; there it ranks ahead of 60.13% of US stocks.
  • RETA's strongest trending metric is Value; it's been moving up over the last 31 weeks.
  • RETA's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).

RETA Stock Summary

  • The ratio of debt to operating expenses for Reata Pharmaceuticals Inc is higher than it is for about just 0.5% of US stocks.
  • With a price/sales ratio of 587.27, Reata Pharmaceuticals Inc has a higher such ratio than 98.57% of stocks in our set.
  • With a year-over-year growth in debt of -100%, Reata Pharmaceuticals Inc's debt growth rate surpasses just 0% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Reata Pharmaceuticals Inc are AKTS, UPLD, FEYE, UGRO, and MODN.
  • Visit RETA's SEC page to see the company's official filings. To visit the company's web site, go to www.reatapharma.com.

RETA Price Target

For more insight on analysts targets of RETA, see our RETA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $232.11 Average Broker Recommendation 1.12 (Strong Buy)

RETA Stock Price Chart Interactive Chart >

Price chart for RETA

RETA Price/Volume Stats

Current price $145.97 52-week high $186.82
Prev. close $146.01 52-week low $76.34
Day low $143.43 Volume 293,000
Day high $147.12 Avg. volume 367,726
50-day MA $105.14 Dividend yield N/A
200-day MA $116.64 Market Cap 5.30B

Reata Pharmaceuticals, Inc. - (RETA) Company Bio


Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.


RETA Latest News Stream


Event/Time News Detail
Loading, please wait...

RETA Latest Social Stream


Loading social stream, please wait...

View Full RETA Social Stream

Latest RETA News From Around the Web

Below are the latest news stories about Reata Pharmaceuticals Inc that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference

PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious

Yahoo | June 7, 2021

Shareholders Will Probably Not Have Any Issues With Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Compensation

Shareholders may be wondering what CEO J. Huff plans to do to improve the less than great performance at Reata...

Yahoo | June 3, 2021

Reata (RETA) Soars on Potential Omaveloxolone NDA Filing

The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.

Yahoo | May 20, 2021

Company News for May 20, 2021

Companies In The News Are: TGT, AMD, AZN, RETA

Yahoo | May 20, 2021

Reata requests pre-NDA meeting for omaveloxolone in Friedreich’s Ataxia

Reata Pharmaceuticals (RETA) has received a communication from the FDA stating that, after a preliminary review of briefing materials for an upcoming Type C meeting, a pre-NDA meeting is the most appropriate format for a discussion of the development program for omaveloxolone in Friedreich’s ataxia ((FA)).The Agency suggested that the...

Seeking Alpha | May 19, 2021

Read More 'RETA' Stories Here

RETA Price Returns

1-mo 86.31%
3-mo 17.96%
6-mo 20.58%
1-year -10.58%
3-year 268.43%
5-year 569.59%
YTD 18.08%
2020 -39.53%
2019 264.40%
2018 98.09%
2017 29.73%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7425 seconds.